ingredientsour brandssustainabilitywhy Givaudan?expert insightsContact Us

The science behind Aronox™

back to
Aronox™

Aronox™ – beneficial effects to support healthy blood flow

Aronox™ is an aronia berry extract rich in polyphenols and in particular, anthocyanins – bioactive compounds found in fruit and vegetables.¹ Evidence from epidemiological and clinical studies suggests that a high intake of polyphenol-rich foods, including berries, may support heart health.⁴ Randomised controlled trials have also shown significant improvements in blood lipids, blood pressure and endothelial function (blood flow) after the consumption of berries and other foods rich in anthocyanins.¹

4
health claims³
1.2%
improvement in endothelial function⁶⁻⁷

Supporting endothelial function to improve blood flow

In a 2019 peer-reviewed publication of a clinical study, 500mg of Aronox™ was shown to have both immediate and long-term effects on the improvement of endothelial function and blood flow (two hours after ingestion and following 90 days of daily consumption).¹ Endothelial cells line the entire circulatory system, from the heart to the smallest capillaries, and control the relaxation (vasodilation) and contraction (vasoconstriction) of blood vessels to manage blood flow⁵. A 1% improvement in endothelial function has been reported to support heart health.⁶ ⁷

Supporting key cardiovascular markers

Other peer-reviewed publications of clinical studies on Aronox™ have demonstrated:

  • 200 mg of aronia polyphenols from Aronox™ has been shown to improve arterial function – measured as augmentation index (AIx) and pulse wave velocity (PWv) and to significantly increase gut microbiome gene richness and the abundance of butyrate-producing species (such as Lawsonibacter asaccharolyticus and Intestinimonas butyriciproducens species) in pre-hypertensive middle-aged individuals.⁸
  • 200 mg of aronia polyphenols from Aronox™ decreases total cholesterol, LDL (“bad”) cholesterol by 11.5 points (p < 0.01) and triglycerides by 27 points (p < 0.05), while maintaining levels of HDL (“good”) cholesterol, in two months in 25 patients with metabolic syndrome.⁹
  • 200 mg of aronia polyphenols from Aronox™ lowers blood pressure, including a decrease in systolic blood pressure (11 mmHg) from high to pre-hypertensive levels (p < 0.000) in just one month in a population of forty-four participants (11 women and 33 men, mean age 66 years) who survived myocardial infarction and have received statin therapy for at least 6 months.¹⁰
  • 200 mg of aronia polyphenols from Aronox™ inhibits the activity of angiotensin converting enzyme (ACE) with a mean decrease of 33.28% (p<0.009) in a population of forty-four participants (11 women and 33 men, mean age 66 years) who survived myocardial infarction and have received statin therapy for at least 6 months. ACE indirectly increases blood pressure by causing blood vessels to constrict, thereby reducing blood flow. ¹⁰ A 2015 in vitro study showed Aronox™ increases levels of nitric oxide. Increased nitric oxide levels have been suggested as a mechanism of action to support vasodilation and blood flow.¹¹
Learn More

Learn More

Multiple approved health claims in Canada³

Aronox™ has been awarded four health claims by Health Canada³:

Helps to support healthy blood flow.

Helps to support healthy endothelial function.

Helps maintain endothelium-dependent vasodilation, which contributes to normal blood flow.

Source of antioxidant(s)/Provides antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals.

References
Disclaimer
This web page is intended to provide business-to-business education and information. Its purpose is not intended to communicate to end consumers. Ingredient information is for educational purposes only; specific ingredients are not intended to prevent, treat, mitigate or cure any disease states. This information is not intended to be used in final consumer products and any use or reference of the intellectual property of Givaudan in the final product may only be made with Givaudan’s prior written permission. The information provided may or may not be applicable to, or satisfy, all regulatory requirements for all global regions. Specific regulatory requirements must be evaluated to ensure compliance within the individual countries and regions.
contactsprivacy policyterms and conditions
*